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Abstract
Background: Non Small Cell Lung Cancer (NSCLC) is the major cause of cancer related-death. Many patients
receive diagnosis at advanced stage leading to a poor prognosis. At present, no satisfactory screening tests are
available in clinical practice and the discovery and validation of new biomarkers is mandatory. Surface Enhanced
Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (SELDI-ToF-MS) is a recent high-throughput
technique used to detect new tumour markers. In this study we performed SELDI-ToF-MS analysis on serum
samples treated with the ProteoMiner™ kit, a combinatorial library of hexapeptide ligands coupled to beads, to
reduce the wide dynamic range of protein concentration in the sample. Serum from 44 NSCLC patients and 19
healthy controls were analyzed with IMAC30-Cu and H50 ProteinChip Arrays.
Results: Comparing SELDI-ToF-MS protein profiles of NSCLC patients and healthy controls, 28 protein peaks were
found significantly different (p < 0.05), and were used as predictors to build decision classification trees. This
statistical analysis selected 10 protein peaks in the low-mass range (2-24 kDa) and 6 in the high-mass range (40-80
kDa). The classification models for the low-mass range had a sensitivity and specificity of 70.45% (31/44) and
68.42% (13/19) for IMAC30-Cu, and 72.73% (32/44) and 73.68% (14/19) for H50 ProteinChip Arrays.
Conclusions: These preliminary results suggest that SELDI-ToF-MS protein profiling of serum samples pretreated
with ProteoMiner™ can improve the discovery of protein peaks differentially expressed between NSCLC patients
and healthy subjects, useful to build classification algorithms with high sensitivity and specificity. However,
identification of the significantly different protein peaks needs further study in order to provide a better
understanding of the biological nature of these potential biomarkers and their role in the underlying disease
process.
Background
Lung cancer is the leading cause of cancer-related
deaths worldwide [1]. More than 80% of lung cancer
patients are affected by non small cell lung cancer
(NSCLC), while the remaining 20% by small cell lung
cancer (SCLC). Most of lung cancer cases are diagnosed
in advanced stages, and only one third of patients with
new diagnosis can undergo surgical treatment that, at
present, is the therapeutic option associated to the best
survival rate (5-ys 70% for Stage I after surgical resec-
tion). Many efforts have been made in the last decade to
improve the percentage of diagnosis at early stage, as
b o t ht h ec h e s tr a d i o g r a p h ya n dt h eH i g hR e s o l u t i o n
Computed Tomography (HRCT) have proved to be
inadequate screening tests [2]. Thus, is necessary to dis-
cover reliable biomarkers for an early and accurate diag-
nosis of the tumor condition.
Biomarker discovery in biological fluids, such as
serum, plasma and urine, is one of the most challenging
aspects of proteomic research. Most investigators believe
that, due to heterogeneity of cancer diseases (histological
grade, tumor stage, patient age, sex and genetic back-
ground), a set of biomarkers, instead of a single cancer-
specific marker, might be more useful in clinical practice
[3,4].
Surface-Enhanced Laser Desorption/Ionization Time-
of-Flight Mass Spectrometry (SELDI-ToF-MS) is a rela-
tively new proteomic technology regarded as one of the
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This is a high through-put technique that allows obtain-
ing protein profiles from several complex biological
samples, with minimal requirements for purification and
separation, in a rapid and efficient way. Small amount of
sample (such as body fluids or tissue cell lysate) is
directly applied on biochips, available with different
chromatographic surfaces (ProteinChip Arrays). Selec-
tively retained proteins are then directly analyzed by
laser desorption and ionization. The result is a mass
spectrum comprised of the mass to charge (m/z) ratio
and intensities of the bound peptide/protein [5]. After-
ward, the statistical analysis of the obtained protein pro-
files permits to reveal any protein changes, with high
sensitivity and specificity. One of the key feature of
SELDI-ToF-MS analysis is its ability to detect a large
number of low-molecular weight proteins ( < 20 kDa),
thus overcoming one of the major limitation of the two-
dimensional gel electrophoresis [6,7]. Furthermore,
other mass spectrometry techniques (such as MALDI or
ESI) may require pre-digestion of whole proteins with
enzymes (for example trypsin) in order to generate pep-
tides small enough to be analyzed. There are however
drawbacks of SELDI-ToF-MS techniques such as com-
petitive binding of high abundance non-informative pro-
teins to the ProteinChip surfaces, and the need of a
second step to identify the protein peaks of interest.
In the last years, this approach has been used to dis-
cover potential biomarkers for the diagnosis of some
types of cancer, such as ovarian [8,9], breast [10,11], col-
orectal [12], and prostate cancer [13,14], as well as for
many other diseases [4,15-18]. Recently, SELDI-ToF-MS
profiling has been applied in a few studies aimed to
identify lung cancer biomarkers analyzing tissue [19-22]
and serum samples [23-28]. Unfortunately, although the
obtained results are quite promising, so far none of the
discovered biomarker has already been validated for the
clinical use. It is well known that the discovery of pro-
tein biomarkers from serum samples is complicated due
to its wide dynamic range (over 10 orders of magni-
tude). In addition, the few high-abundant blood species
constitute 95% of the total protein content, representing,
at the same time, less than 0.1% of the total proteins
[3,29], making very difficult the detection of the low-
abundant components. The ProteoMiner™ technology
is a novel approach, consisting of a combinatorial library
of beads-coupled hexapeptide ligands, that assures the
capture of all protein species present in a proteome
enhancing the concentration of the most dilute ones
[30-32]. The beads work on the principle of solid-phase
affinity adsorption; each specie has theoretically the
same probability to bind to its high affinity ligand. The
most abundant proteins quickly saturated their binding
sites, while the low and medium abundance proteins are
concentrated on their specific ligands. At the end, only
retained proteins are eluted and collected, while the
excess proteins are washed away.
No depletion of any species is contemplated by this
methodology, but a reduction of the relative concentra-
tion of the abundant components and a strong decrease
of the sample dynamic range.
In this study, before investigating the proteomic pro-
file of patients with NSCLC in comparison with healthy
subjects, we treated serum samples with the ProteoMi-
ner™ kit. Our goal was to verify, by SELDI-ToF-MS
analysis, the presence of specific protein patterns in
enriched serum samples, able to discriminate NSCLC
patients from healthy subjects.
Methods
Study population and clinical specimens
Whole blood samples (10 mL) were collected immedi-
ately before surgery in a test tube and allowed to clot at
room temperature for 1 h. After centrifugation at 2000
× g for 10 min at 4°C, serum was divided in aliquots
and immediately stored at -80°C until use.
Serum samples from 44 NSCLC patients and 19 from
healthy subjects were analyzed.
All NSCLC cases were candidate to complete surgical
resection. Moreover, no patient underwent induction
chemotherapy before surgery. The histological distribu-
tion was: 28 adenocarcinomas and 16 squamous carci-
nomas (histological diagnosis according to the World
Health Organization 2004 classification of lung tumors).
Patients were staged according to the new 2009 IASLC
(International Association for the Study of Lung Cancer)
staging system. Pathologic stage distribution was as fol-
lows: 15 stage IA, 12 stage IB, 5 stage IIA, 4 stage IIB, 7
stage IIIA, and 1 stage IIIB (multiple nodules in differ-
ent lobes). The mean age was 71 years, (range 51-88
years, STD 8 years); 9 female and 35 males. Nineteen
healthy volunteers were selected as controls; the mean
age was 68 years; range 47-82 years, STD 10 years, 4
females and 13 males (no statistical difference was pre-
sent between cases and control regarding gender and
age). The main inclusion criteria for this group was the
absence of pulmonary diseases proved by a recent chest
X-Ray. The present study was performed according to a
protocol approved by the Ethical Committee of the Uni-
versity Hospital of Modena, Italy. Voluntary informed
consent to donate serum was obtained for all research
participants.
Protein enrichment
ProteoMiner™ Protein Enrichment kit (BioRad Labora-
tories Inc., Hercules, CA, USA) was utilized according
to the manufacturer instructions. Briefly, 1 mL of serum
was added to spin columns containing the beads and
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end-to-end rotation. After columns wash, the proteins
bound to the beads were eluted with the appropriate
buffer, divided in aliquots and stored at -20°C until use.
In order to obtain a quality control (QC) sample as
similar as possible to the analyzed samples, 20 μLo f
each sample treated with the ProteoMiner™ kit were
pooled and used for all the experiments. Protein con-
centration of each sample was assessed using an assay
based on the Bradford method [33].
SELDI-ToF-MS protein profiling
Enriched serum samples were analyzed with SELDI-
ToF-MS, with the purpose to investigate the protein
profile in both the low (2-30 kDa) and the high (30-100
kDa) molecular weights (MW). In a preliminary study,
in order to set up the experimental conditions, pooled
serum samples were loaded onto three different types of
ProteinChip Arrays (Bio-Rad Laboratories Inc., Hercules,
CA, USA): H50 (that binds proteins through reverse-
phase or hydrophobic interactions), CM10 (negatively
charged surface that acts as a weak cation-exchanger)
and IMAC30-Cu (Immobilized Metal Affinity Capture
surface pre-activated with copper). The CM10 array
gave the lower number of peaks detected (~ less than
10%) and the lower total signal intensity (~ less than
50%) compared to H50 and IMAC30-Cu, so only these
two arrays were used in the main study.
In order to minimize any bias sources, each sample
was randomly loaded in duplicate in a 96 well biopro-
cessor. Moreover, to assess the reproducibility, a QC
sample was included in each ProteinChip array and all
steps were automated using a robotic instrument for
liquid handling (Biomek 3000 Laboratory Automation
Workstation, Beckman Coulter, Fullerton, CA, USA).
Ten microliters of diluted serum sample (3 μg/μL final
concentration) were mixed with 90 μLo fb i n d i n gb u f f e r
and loaded onto pre-equilibrated ProteinChip Array
spot surfaces. After 45 min incubation at room tempera-
ture with constant horizontal shaking, the unbound pro-
teins were removed by three washing steps using 200 μL
of the same binding buffer. Finally, 1 μL of saturated
sinapinic acid solution in 0.5% trifluoroacetic acid and
50% acetonitrile (Sigma-Aldrich, St.Louis, MO, USA)
was applied to each spot twice, allowing the surface to
dry between each application.
Data acquisition
The ProteinChip Arrays were analyzed with a SELDI-
ToF-MS reader (Series 4000, Bio-Rad Laboratories Inc.,
Hercules, CA, USA), by protocols optimized for low and
high MW ranges. Protein mass spectra were generated
using an average of 901 laser shot for each protocol.
The “All-in-one protein standard II” (Bio-Rad
Laboratories Inc., Hercules, CA, USA) was used to
obtain protein standard spectra for mass accuracy
calibration.
Statistical analysis
Statistical analysis was performed using the ProteinChip
Data Manager 3.0 software (Bio-Rad Laboratories Inc.,
Hercules, CA, USA). The spectra were mass calibrated,
baseline subtracted, mass aligned and finally normalized
by total ion current in both the MW ranges of interest.
All poor quality spectra were excluded from the statisti-
cal analysis. Supervised clustering was performed using
the following settings: 5 times signal-to-noise (S/N) ratio
and 20% min peak threshold in the first pass for peaks
identification, and 2 times S/N ratio on the second pass
for cluster completion.
After clusters identification, to test the null hypothesis
that the medians of peak intensities of the two groups
were equal, Mann Whitney U test was performed. A p-
value less than 0.05 was accepted as statistically
significant.
To test the overall quality of the assay, QC sample
spectra replicates were used to calculate pooled CV%.
This was obtained, for each protocol, using the intensity
CV % of 20 representative cluster peaks, regularly dis-
tributed for mass ranges and peak intensities, including
all the statistical significant peaks. The pooled CV %
means were 23.4% and 24.5% in the low-mass range,
and 22.2% and 24.1% in the high- mass range, for
IMAC30-Cu and H50, respectively.
Decision tree classification
Decision tree classification was performed using Biomar-
ker Pattern Software 5.0 (Ciphergen, USA) based on
CART (Classification And Regression Trees) as
described by Breiman et al. [34]. Classification tree split
u pad a t as e ti n t on o d e su s i n go n er u l ea tat i m e .F o r
each node the decision is made by the presence or
absence or the intensity level of one peak until a term-
inal node is reached or further splitting has no gains.
Classification was performed using as target the group
(class), the Gini method, and 10-fold cross-validation,
and as predictors all the peaks with a statistical signifi-
cance between NSCLC and controls (p-value < 0.05).
Peaks selected by this process are the ones present in
the lowest cost trees. The 10-fold cross- validation test
divided the data set into approximately 10 equal subsets.
The tree-growing process is repeated from scratch 10
times and in each cross-validation replication nine sub-
sets of the data are used as learning data and one subset
is used as a test sample. At the end of process, the error
counts from each of the 10 test samples are summed to
obtain the overall error count for each tree in the full-
sample tree sequence.
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A total of 63 enriched serum samples were analyzed by
SELDI-ToF-MS with both IMAC30-Cu and H50 Pro-
teinChip Arrays. For each reading protocol, the MS
spectra were processed as described above. A total of
106 cluster peaks (88 in the low- and 18 in the high-
MW) for IMAC30-Cu, and 95 peaks (73 in the low- and
22 in the high-MW) for H50 were detected. Non-para-
metric Mann-Witney U test was carried out to verify
the presence of peaks with statistically significant rela-
tive intensities between NSCLC patients and control
subjects. Using IMAC30-Cu, 9 significant peaks (6 in
the low-MW range and 3 in the high-MW range) were
found comparing NSCLC patients to controls. With
H50 ProteinChip Array, 19 significant peaks (14 in the
low-MW and 5 in the high-MW) were obtained. These
differentially expressed peaks (Additional file 1, Table
S1) were used to construct decision trees classification
algorithms, in the attempt to identify potential serum
biomarkers for NSCLC.
For IMAC30-Cu, 6 statistically different protein peaks
in the low-MW range were chosen as predictor to build
up the decision classification tree shown in Figure 1.
The classification algorithm used 4 protein peaks and 6
terminal node were determined with a relative cost of
0.61. The accuracy of this algorithm was 93.65% (59/63),
which correctly classified 41 of 44 NSCLC (93.18%) and
18 of 19 healthy controls (94.74%). The accuracy after
10-fold cross-validation was 69.84%, with sensitivity of
70.45% (31/44) and specificity of 68.42% (13/19). In
Table 1 are listed the 4 protein peaks: 3 were up-regu-
lated (2664, 4466, 8934 m/z), and 1 was down-regulated
(12451 m/z) in NSCLC patients. Figure 2 shows repre-
sentative spectra of these protein peaks in NSCLC
patients and controls.
T h es a m ea n a l y s i sw a sc a r r i e do u tw i t hH 5 0P r o -
teinChip Array, using as predictors 14 significant peaks
found in the low-MW range; the classification algorithm
selected 5 protein peaks, reported in Table 2. Three of
these peaks were up-regulated (9365, 9712, and 23972
m/z) and 2 were down-regulated (7612 and 12455 m/z)
in NSCLC patients compared with controls. Representa-
tive spectra are shown in Figure 3. The classification
decision tree generated 6 terminal nodes with a relative
cost of 0.536 (Figure 4). The decision algorithm cor-
rectly classified 42 of 44 NSCLC patients (95.45%) and
18 of 19 controls (94.74%), with an accuracy of 95.23%
(60/63). After crossing validation, the accuracy
decreased to 73.01% (46/63) with sensitivity of 72.73%
(32/44) and specificity of 73.68% (14/19).
Decision classification trees were also obtained using
as predictors the statistically significant peaks detected
in the high-mass range (30-100 kDa) for IMAC30-Cu
(Additional File 2, Figure S1) and H50 (Additional File
3, Figure S2). Two peaks were selected by this process
for IMAC30-Cu and 3 peaks for H50, respectively
(Table 3). In this case, the relative cost and the misclas-
sification rate were higher than those obtained in the
low-MW. Actually, after 10-fold-cross-validation, 31 of
44 NSCLC patients (70.45%) and 6 of 19 control sub-
jects (68.42%) using IMAC30-Cu, and 21/44 NSCLC
(47.73%) and 9 of 19 (52.63%) controls with H50 Pro-
teinChip Arrays, were correctly classified.
Finally, all the 28 statistically significant peaks, identified
in all experimental condition, were used as predictors to
build an unique decision classification tree (Additional
File 4, Figure S3). This algorithm used 5 protein peaks:
3 already selected in other decision algorithms (7612,
8934 and 12455 m/z) and 2 new peaks (12588 and
44689 m/z) (Additional File 5, Table S2).
The decision algorithm correctly classified 40 of 44
NSCLC patients (90.91%) and 18 of 19 controls
(94.74%), with an accuracy of 92.06% (58/63). After
crossing validation, the accuracy decreased to 61.90%
(39/63) with sensitivity of 65.91% (29/44) and specificity
of 52.63% (10/19).
Discussion
The incidence of lung cancer is constantly increasing,
with an high mortality rate due to delay in diagnosis.
For this reason, early NSCLC biomarkers could be cru-
cial for the diagnosis, prognosis and follow-up. Many
studies have been made in the past years in the attempt
to discover reliable biomarkers, but, to date, their poor
organ and tumor specificity limits their use to prognosis
and therapy monitoring [35].
In order to discover novel protein biomarkers, a num-
ber of different technologies are used. Among these
techniques, SELDI has the advantage to allow direct
protein profiles of biological fluids (such as serum or
urine) in a rapid and reproducible way. This generate an
huge amount of data that can be directly analyzed with
the bioinformatics tools coupled with the system.
Although this technology was successfully applied for
the discovery of candidate biomarker in different tumor
types, currently, in literature, only few SELDI-ToF-MS
studies on lung cancer are reported, especially per-
formed on crude serum samples, without any prelimin-
ary pre-fractionation or depletion treatment. For
example, Han et al. [26] analyzed, on H4 ProteinChip
Array, untreated serum from patients with SCLC,
NSCLC, pneumonia and from healthy individuals, defin-
ing 3 different protein patterns able to discriminate
SCLC from controls and the different diseases with each
other. Some authors used CM10 ProteinChip Array to
compare crude serum of lung cancer patients and
healthy controls. Although the same ProteinChip type
was used, they discovered different protein peaks,
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identified a protein peak at 11.6 kDa (serum Amyloid A
protein), able to discriminate lung cancers from controls
with a sensitivity of 84% and specificity of 80% [25].
Yang et al. [23] detected 5 protein peaks at m/z 11493,
6429, 8345, 5335 and 2538 that were chosen to build a
classification algorithm. It permitted to discriminate
stages I and II of NSCLC with a sensitivity of 91.4% and
79.1%, respectively. More recently, Yang et al. [28] dis-
covered and validate 3 candidate biomarkers in NSCLC:
Figure 1 Decision tree classification diagram of low-MW serum protein peaks from NSCLC patients and controls, applying the
IMAC30-Cu conditions. The numbers in the root (top), descendant nodes (exagons) and terminal nodes (rectangles), represent the classes
(NSCLC and controls, N = sum of NSCLC and controls subjects). The numbers below the root and the descendant nodes indicate the values of
mass peak and its intensity, respectively.
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2664 8.672 ± 4.215 6.142 ± 2.948 0.020
4466 234.807 ± 56.203 195.299 ± 63.867 0.046
8934 2503.941 ± 516.768 2303.279 ± 247.386 0.022
12451 4.182 ± 3.304 6.471 ± 4.294 0.036
Figure 2 Serum protein profile of low-MW predictor peaks (IMAC30-Cu). Representative spectra (in duplicate) obtained by SELDI-ToF-MS
analysis concerning the 4 statistically significant peaks detected with IMAC30-Cu and used as predictors to build the decision classification tree
shown in Figure 1. The peaks of interest are highlighted in rectangles and their m/z values are reported above. (Ctrl = control subjects).
Table 2 Comparison of low-MW predictor protein peaks






7612 1.051 ± 0.681 1.847 ± 0.836 0.001
9365 4.269 ± 1.403 3.353 ± 0.871 0.019
9712 3.764 ± 2.797 1.919 ± 0.518 0.002
12455 0.702 ± 0.674 0.886 ± 0.483 0.019
23972 0.064 ± 0.025 0.052 ± 0.033 0.030
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(6628 Da), and 2 up-regulated, haptoglobin alpha-1
chain (9191 Da) and S100A4 (11412 Da). Moreover,
other ProteinChip Arrays, such as IMAC-30, were used
to perform SELDI-ToF analysis on crude serum samples
from lung cancer patients [27].
The only work on pretreated serum samples is by Au
et al. [24]: they used the Equalizer beads, the developing
combinatorial library ligands technology that was then
commercialized with the trade name ProteoMiner. They
treated serum from never-smoked lung cancer patients
and normal control subjects using IMAC30 and Q10
ProteinChip Array. Comparing the serum proteomic
profiles of patients with controls, they found several sta-
tistically significant protein peaks, mostly in the high
mass-range ( > 50 kDa).
Unlike the majority of the previous studies reported in
literature, we conducted a SELDI-ToF-MS analysis on
Figure 3 Serum protein profile of low-MW predictor peaks (H50). Representative spectra (in duplicate) obtained by SELDI-ToF-MS analysis
concerning the 5 statistically significant peaks detected with H50 ProteinChip Array and used as predictors to build the decision classification
tree shown in Figure 4. The peaks of interest are highlighted in rectangles and their m/z values are reported above. (Ctrl = control subjects).
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teoMiner™kit. This technique has the main advantage
to reduce the serum high dynamic range by lowering
the concentration of most abundant protein species and
simultaneously concentrating the less abundant ones.
Other different depletion methods, based on dye-ligands
or specific antibodies, are currently available but they
could produce some drawbacks, such as co-depletion
[ 3 6 ] .I ti sw i d e l yd e m o n s t r a t e dt h a tt h eP r o t e o M i n e r ™
technique is able to increase the recovery yield of pro-
tein species detected with two-dimensional gel electro-
phoresis and SELDI-ToF-MS analysis, preserving their
proportionality. This permits to reveal low and medium
abundance proteins in serum and plasma samples, as
needed for biomarker discovery [37-39].
In the present work we treated with this new
approach serum samples from 44 NCSLC and 19
healthy controls, obtaining 106 cluster of protein peaks
for IMAC30-Cu and 95 for H50 ProteinChip Arrays,
respectively. The comparison of the clusters between
the two group identified 28 cluster peaks (20 in the low
and 8 in the high mass range) statistically different (p <
0.05) and they were used as predictors to build decision
classification algorithms (4 classifications built consider-
ing ProteinChip type and MW separately, and 1 built
considering all conditions). These analyses selected 4
peaks in the low- and 2 peaks in the high-MW for
IMAC30-Cu, and 5 in the low- and 3 in the high-MW
for H50. The classification models for the low-mass
range after 10-fold cross-validation had a sensitivity of
Figure 4 Decision tree classification diagram of low-MW protein peaks from NSCLC patients and controls, using H50 conditions.T h e
numbers in the root (top), descendant nodes (exagons) and terminal nodes (rectangles), represent the classes (NSCLC patients and controls, N =
sum of NSCLC and controls). The numbers below the root and descendant nodes indicate the values of mass peak and its intensity, respectively.
Table 3 Comparison of high-MW range predictor peak








45973 1.514 ± 0.448 1.097 ± 0.331 0.001
80313 0.134 ± 0.073 0.172 ± 0.094 0.050
H50
34527 2.346 ± 0.569 2.039 ± 0.497 0.036
51996 0.327 ± 0.326 0.255 ± 0.338 0.026
73503 0.128 ± 0.010 0.066 ± 0.031 0.025
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IMAC30-Cu, and 72.73% (32/44) sensitivity and 73.68%
(14/19) specificity for H50 ProteinChip Array. The clas-
sification algorithm built with all cluster identified in all
experimental conditions allowed to single out two more
peaks, even if this algorithm had a lower classification
power, 65.91% (29/44) sensitivity and 52,63% (10/19)
specificity.
When compared with other studies present in litera-
ture, the use of ProteoMiner™ kit permits to increase
the number of significant peaks able to discriminate
NSCLC patients from healthy controls. In fact, although
the limited number of enrolled subjects and considering
the relatively heterogeneity of cases regarding disease
stage, a total of 16 interesting protein peaks were dis-
covered, mostly in the low mass range. It is also impor-
tant to note that all cases enrolled came from a surgical
series and all patients with a clearly metastatic disease
(stage IV) were excluded. This point addresses the pos-
sibility to discover potential candidate biomarkers to dif-
ferentiate patients amenable of a surgical treatment at
diagnosis, that is the therapeutic option associated to
the best survival rate.
Conclusions
In summary, in our study we used the ProteoMiner™ kit
prior to SELDI-ToF-MS analysis to reduce the complexity
of NSCLC and controls serum samples. Statistical analysis
of differentially expressed protein peaks has permitted to
build algorithms, that could discriminate between NSCLC
patients and control subjects, with high rate of sensitivity
and specificity. Our results show that the SELDI-ToF-MS
technology coupled with the ProteoMiner™ strategy is
able to identify a set of protein peaks as candidate biomar-
kers, in a rapid and high-throughput mode. These protein
peaks could be useful to select, among patients at risk to
develop lung cancer (such as heavy smokers > 40 years),
those that require an aggressive radiological follow up, in
order to discover the neoplastic condition at an early
stage. However, further studies, increasing the number of
patients and controls, are needed to confirm these results
and especially to identify and subsequently validate the
discovered protein peaks.
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